Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
Organisation › Details

Neurimmune AG

Neurimmune is a biopharmaceutical company dedicated to the development of human-derived therapeutic antibodies for the treatment and prevention of human diseases with a high unmet medical need. Established in 2006, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease, partnered with Biogen, is currently in phase 3 clinical trials. Rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were acquired by Biogen. In 2016, Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. In 2017, Neurimmune entered into a collaboration with Ono Pharmaceutical in Japan. Neurimmune’s pipeline includes human antibody programs for cardiomyopathy, type-2 diabetes and progressive multifocal leukoencephalopathy, with potential therapies in advanced preclinical stages. *

 

Period Start 2006-11-01 established
Products Industry CNS drug
  Industry 2 RTM® technology (Reverse Translational Medicine)
Persons Person Nitsch, Roger M. (Neurimmune 201809 CEO + Co-Founder + Evotec Biosystems 199906 Scientific Advisory Board)
  Person 2 Salzmann, Michael (Neurimmune 2008– COO + General Manager before Bruker + Roche + ETH Zürich)
     
Region Region Schlieren ZH
  Country Switzerland
  Street 13 Wagistr.
  City 8952 Schlieren ZH
  Tel +41-44-755-4646
    Address record changed: 2018-07-24
     
Basic data Employees A: 1 to 10 (2007-12-09)
     
    * Document for �About Section�: Neurimmune AG. (4/26/18). "Press Release: Neurimmune Appoints Fabian Buller as Chief Business Officer". Schlieren.
     
   
Record changed: 2019-04-11

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

More documents for Neurimmune AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top